12 years ago

Pulmocide Secures £17 Million Series A Funding for Inhaled Medicines

  • Pulmocide, a UK-based company developing inhaled medicines for serious respiratory infections, raised £17 million in Series A funding

  • The round was led by Imperial Innovations Group plc, with participation from SV Life Sciences, Fidelity Biosciences, and Johnson & Johnson Development Corporation

  • Pulmocide, led by Garth Rapeport and Pete Strong, will be based at the Imperial BioIncubator in London.

      • ProblemHealthcare

      "serious viral and fungal infections of the respiratory tract are difficult to treat effectively."

      Solution

      "Pulmocide is developing a new generation of inhaled medicines to treat respiratory infections."

      Covered on